Very proud of our recent PGY1 pharmacy resident Kaylee Whitenack for getting this through to publication!
Much more to sort out, but albumin appears important for outcomes in MSSA bacteremia.
Small study, but super interesting findings! SNAP might provide more info!
🆕️✨️Impact of Hypoalbuminemia on Clinical Outcomes in Patients Receiving Cefazolin for MSSA Bacteremia #idxposts
https://t.co/FCDh8XjNYk
A study led by Dr. @InfectiousDan Ilges, at Mayo Clinic Arizona found that excluding #Cdifficile from gastrointestinal pathogen panels reduced unnecessary treatments, improved diagnostic accuracy, and caused no delays in diagnosis.
Read more: https://t.co/DLWrwTlUKh
🆕️⚡️⚡️Quasi-experimental, pre/post, retrospective cohort
Positive impact of a diagnostic stewardship intervention
Following gastrointestinal pathogen panel C. difficile target removal, GIPP orders 🔽 from 3.23 to 2.7 per 1,000 patient visits (P < .001)
https://t.co/w2IfSTTF1Q
HIV viral load dropped 3.5 logs after 11 doses of Biktarvy per given per tube for patient on CRRT and ECMO. I told the team we’re crushing it. #twitterx
Evaluation of multisite programmatic bundle to reduce unnecessary antibiotic prescribing for respiratory infections: A retrospective cohort study
✅ Just Accepted
🔓 Open Access
🔗 https://t.co/kwAhSBAdek
via @InfectiousDan@Stevens_AK@AbinashVirkMD@pascalisID
🆕️🔥Retrospective, multicenter, cohort study
Twice daily cephalexin is as effective as four times daily dosing for for the treatment of uncomplicated UTI with a cefazolin-susceptible urine culture #IDXposts https://t.co/XcGSUQqFm2
🆕️🔥Retrospective, multicenter, cohort study
Twice daily cephalexin is as effective as four times daily dosing for for the treatment of uncomplicated UTI with a cefazolin-susceptible urine culture #IDXposts https://t.co/XcGSUQqFm2
🆕️⚡️🔥Retrospective cohort study suggests that short (≤10 days) antimicrobial courses had comparable 90-day outcomes as intermediate and prolonged regimens for GN-BSI among immunocompromised patients with neutropenia #IDTwitter@IDdocAdi@BradSpellberg
https://t.co/5A61vxca7O
With the latest CLSI breakpoints, tobramycin is the only reliable aminoglycoside for Pseudomonas if you ever need one (Susceptible: MIC ≤1)
Amikacin: can still be used for UTI (Susceptible: MIC ≤ 16)
Gentamicin: RIP ☠️
From @seausman, @MsSmallsO et al
Analysis of antimicrobial stewardship intervention acceptance rate at a multisite heath system showed female & male clinicians were equally effective at prospective audit and feedback
📄: https://t.co/kfLWdw86KZ
Attention #IDtwitter - there’s still time to apply to our ID Rph clin specialist opening! Come work with our wonderful @MayoAZINFDIS team. Provide world-class care in beautiful AZ.
- cocci
- transplant
- stewardship
- research
- teaching
- and more!
https://t.co/LDr3q1WVb9